Kenvue's Strategic Agency Shift, Vaccine Policy Challenges, and Medtech Industry Transformations
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
このコンテンツについて
This episode moves from brand strategy to public health strategy, and shows how leadership choices ripple through both worlds. We start with Kenvue’s global agency shakeup, bringing WPP and Publicis into clearly defined lanes as the company looks to streamline execution and push growth across a $1.6B ad footprint. Then we zoom out to 2026’s vaccine reality: mandates, access, and the race to develop new vaccines, all colliding with politics, logistics, and trust.
From there, we connect the dots to a year of medtech turbulence: lawsuits, ERP failures, M&A, leadership turnovers, layoffs, and regulatory pressure shaping how companies operate. Finally, we end with a concrete medical milestone: the first FDA-approved treatment for TA-TMA, a rare and severe complication after stem cell transplants, and what it signals about the future of targeted therapies.
In this episode: • Why Kenvue’s partner model matters for speed, accountability, and scale • What vaccine policy fights reveal about trust and governance • The medtech stories that defined 2025’s risk landscape • A breakthrough FDA approval that could change outcomes for transplant patients
Thanks for listening to this episode. We also discuss the challenges facing vaccine policy in 2026, including debates over mandates, distribution to underserved communities, and the development of new vaccines for emerging diseases.
In the medtech industry, 2025 was marked by significant changes, such as Zimmer Biomet's lawsuit against Deloitte and Johnson & Johnson's major acquisitions. Leadership shifts and strategic refocusing were prevalent, with companies like Olympus and Medtronic adapting to evolving market demands.
Finally, we highlight Omeros's groundbreaking FDA-approved treatment for a severe stem cell transplant complication, showcasing the potential of targeted therapies in addressing complex medical challenges.
Join us as we navigate these dynamic stories and their implications for the future.
Stan Berteloot is a French journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.
As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.
Start your VoiceStream free trial today!
Stan Berteloot is a French journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture. As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics. Start your VoiceStream free trial today!